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At the start, all patients are in class III or IV. The risks of
hospitalization, death and change in class are considered
on a monthly basis, depending on current NYHA class.
Hospitalizations and deaths are accumulated over 1 year
and survival is quality-adjusted according to class. Direct
medical costs of treatment, hospitalizations and deaths
from a third-party payor perspective are reported in 2002
Canadian dollars. RESULTS: In 1,000 patients (class III:
19%, IV: 81%), treating anemia improves severity (class
I: 4%, II: 61%, III: 19%, IV: 15%), whereas without
treatment there is deterioration: class III: 13%, IV: 87%.
Over one year, this results in avoidance of 108 hospital-
izations and 24 deaths, increased survival of 142 months
(a 51% increase in quality-adjusted life-months) and
savings of over $1.2 million. Treatment with erythropoi-
etin and intravenous iron will cost on average $3,680 per
year per patient. Thus, improving one patient from class
III or IV to I or II costs $4,380, a cost-effectiveness ratio
of $13,620 per QALY. CONCLUSION: The enormous
improvement in NYHA class with anemia treatment in
CHF would result in very cost-effective improvement in
quality of life and in survival.
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OBJECTIVE: It is well recognized that major
atherothrombotic events are associated with substantial
resource use, translating to signiﬁcant economic burden.
The impact of peripheral arterial disease (PAD) is less
clear. In this study, we described the resource use associ-
ated with a diagnosis of PAD relative to stroke and
myocardial infarction (MI). METHODS: Hospitalization
records were examined for 16,440 patients diagnosed
with PAD in Saskatchewan, Canada between 1985–1995,
and compared to records for patients suffering a stroke
(18,704) or MI (15,590) between 1990–1995; all fol-
lowed to December 2000. Hospitalization rates for any
cause, cardiovascular disease (CVD) and bleeding events
in the ﬁve years following diagnosis were estimated and
compared across diagnoses. RESULTS: Approximately
half of PAD (45%) and stroke (52%) patients and 36%
of MI patients are female. Mean age ranged from 67–70
years of age across groups. Overall, between 73% and
86% of patients were hospitalized at least once, with the
PAD group experiencing the greatest frequency (mean =
5.2, sd = 5.0) compared to MI (4.8, 4.5) and stroke (3.9,
3.9). In year one, rates of all-cause hospitalization were
0.86, 1.08, and 0.85 per patient year (PY) for PAD, MI,
and stroke, respectively; for CVD hospitalization they
were: 0.17, 0.35, and 0.21 per PY. In year two, the rate
of all-cause hospitalization was highest for PAD patients
(0.62 vs. 0.58 per PY for stroke and MI) and remained
above or equal to that for MI and stroke in years three,
four, and ﬁve. Similar patterns were observed for CVD
hospitalizations, while rates for bleed-related hospitaliza-
tions were essentially equivalent. CONCLUSIONS: A
diagnosis of PAD is associated with substantial resource
utilization comparable to that observed among patients
suffering a major atherothrombotic event. The economic
implications of a PAD diagnosis ought to be taken as seri-
ously as that of MI and a stroke.
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OBJECTIVE: To compare ﬁve choices to initiate antihy-
pertensive pharmacotherapy as a function of persistence
with treatment and drugs cost. METHODS: An admin-
istrative database, held by the Local Health Unit of
Ravenna, recording pharmacy claims was used to
perform an observational study of patients receiving anti-
hypertensive drugs for the ﬁrst time. All new users, 20
years-old or over, receiving a prescription for amlodipine,
atenolol, fosinopril, indapamide or losartan between
January 1st, 1997 and December 31st, 1997 were
enrolled. The follow up period lasted 365 days. A
bayesian cost-effectiveness analysis based on Markov
Chain Monte Carlo simulations was performed. Persis-
tence with treatment (a duration of therapy on any anti-
hypertensive drug more than 273 days) at a correct
dosage (within the therapeutic range recommended by the
JNC VI) was assumed as a proxy to deﬁne effective ther-
apies. Drugs cost was evaluated at NHS purchase prices.
RESULTS: A total of 4614 subjects was enrolled (22.8%
on amlodipine, 44.0% on atenolol, 18.8% on fosinopril,
6.7% on indapamide, and 7.8% on losartan). The annual
average cost of treatment ranged between €44.27 
(95% CI 38.18–52.06) for those started on atenolol to 
€175.65 (95% CI 150.37–205.10) for those started on
losartan. The average probability of an effective antihy-
pertensive treatment ranged from 8.40% for those initi-
ated on fosinopril to 18.36% for those initiated on
losartan. As a consequence, the choice to initiate antihy-
pertensive treatment on losartan displayed a probability
of being more cost-effective equal to 0.99 compared to
fosinopril, 0.94 to amlodipine, 0.84 to indapamide, and
0.75 to atenolol. CONCLUSION: The low reproducibil-
ity of ﬁndings from experimental studies to clinical prac-
tice should encourage health care providers to account
and assess both resources and associated outcomes in a
“real world” setting: the availability of a linkage between
these variables could affect the cost-effectiveness of
selected choices.
